

References for CEQUA® (cyclosporine ophthalmic solution) 0.09%

1. Schechter BA, Urbieta M, Bacharach J, et al. Effect of OTX-101 on patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the phase 2b/3 clinical trial. *Clin Ophthalmol.* 2022;16:4145-4151.
2. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology.* 2019;126(9):1230-1237.
3. Karpecki P, Barghout V, Schenkel B, et al. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. *BMC Ophthalmol.* 2023;23(1):443.
4. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol.* 2018;12:1921-1929.
5. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.
6. CEQUA [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
7. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: A pooled analysis of phase 2b/3 and phase 3 studies. *Cornea.* 2019;38:1259-1265.
8. Johnston, J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12, 2023; New Orleans, LA.
9. Effect of CEQUA in Subjects with Dry Eye Disease, ClinicalTrials.gov identifier NCT04357795. Updated Feb 06, 2024. Accessed August 21, 2024. <https://www.clinicaltrials.gov/study/NCT04357795>
10. White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. *Clin Ophthalmol.* 2019;13:2285-2292.
11. Sheppard J, Bergmann M, Schechter BA, Luchs J, Ogundele A, Karpecki P. Phase 3 efficacy (worse-eye analysis) and long-term safety evaluation of OTX-101 in patients with keratoconjunctivitis sicca. *Clin Ophthalmol.* 2021;15:129-140.
12. US Patent 9,937,225 B2.
13. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. *Transl Vis Sci Technol.* 2015;4(3):1-16.
14. Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. *J Control Release.* 2017;248:96-116.
15. Cholkar K, Patel A, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. *Recent Pat Nanomed.* 2012;2(2):82-95.
16. Xiidra® [package insert]. Bridgewater, NJ: Bausch & Lomb, Inc.; 2023.
17. Restasis® [package insert]. Irvine, CA: Allergan; 2017.

© 2024 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.
PM-US-CQA-1658 08/2024

